1. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients
- Author
-
Diray-Arce, Joann, Fourati, Slim, Doni Jayavelu, Naresh, Patel, Ravi, Maguire, Cole, Chang, Ana C, Dandekar, Ravi, Qi, Jingjing, Lee, Brian H, van Zalm, Patrick, Schroeder, Andrew, Chen, Ernie, Konstorum, Anna, Brito, Anderson, Gygi, Jeremy P, Kho, Alvin, Chen, Jing, Pawar, Shrikant, Gonzalez-Reiche, Ana Silvia, Hoch, Annmarie, Milliren, Carly E, Overton, James A, Westendorf, Kerstin, IMPACC Network, Cairns, Charles B, Rouphael, Nadine, Bosinger, Steven E, Kim-Schulze, Seunghee, Krammer, Florian, Rosen, Lindsey, Grubaugh, Nathan D, van Bakel, Harm, Wilson, Michael, Rajan, Jayant, Steen, Hanno, Eckalbar, Walter, Cotsapas, Chris, Langelier, Charles R, Levy, Ofer, Altman, Matthew C, Maecker, Holden, Montgomery, Ruth R, Haddad, Elias K, Sekaly, Rafick P, Esserman, Denise, Ozonoff, Al, Becker, Patrice M, Augustine, Alison D, Guan, Leying, Peters, Bjoern, and Kleinstein, Steven H
- Subjects
screening and diagnosis ,IMPACC Network ,SARS-CoV-2 ,longitudinal modeling ,Prevention ,COVID-19 ,systems immunology ,multi-omics ,Multiomics ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,Rare Diseases ,Good Health and Well Being ,immunophenotyping ,Clinical Research ,Disease Progression ,Humans ,2.1 Biological and endogenous factors ,Longitudinal Studies ,Aetiology - Abstract
The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28days), ranging from milder (TG1-3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.
- Published
- 2023